This is true for the oral chemotherapeutic ibrutinib, used to treat chronic lymphocytic leukemia (CLL), which makes roughly equal contributions to hepatic and intestinal CYP3A4 metabolism [51]. The gene discussed is CYP3A4; the disease is B-cell chronic lymphocytic leukemia.